Home > Boards > US OTC > Biotechs > Ampio Pharmaceuticals, Inc (AMPE)

From last PR:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
MrGuru Member Profile
 
Followed By 1
Posts 147
Boards Moderated 0
Alias Born 05/08/17
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/7/2019 4:34:23 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/31/2019 4:31:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2019 6:03:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/21/2019 4:36:09 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 10/16/2019 4:03:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/10/2019 4:02:31 PM
Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility PR Newswire (US) - 10/10/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:02:57 PM
Ampio Retains Legal Counsel for Transaction Advisory Committee PR Newswire (US) - 9/18/2019 8:30:00 AM
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial PR Newswire (US) - 9/17/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:47:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:32:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:13:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/23/2019 4:03:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/22/2019 3:05:35 PM
Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee PR Newswire (US) - 8/22/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 4:04:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/1/2019 5:23:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/1/2019 5:01:31 PM
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial PR Newswire (US) - 7/25/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/11/2019 4:02:23 PM
Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor PR Newswire (US) - 7/11/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/10/2019 4:03:12 PM
Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer PR Newswire (US) - 7/10/2019 8:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/20/2019 3:47:52 PM
MrGuru   Thursday, 09/19/19 07:29:01 AM
Re: None
Post # of 739 
From last PR:

"The FDA has given written guidance that prior study AP-003-A qualifies as a pivotal trial, and that successfully passing the current study, AP-013, would support the filing of our BLA."

"In fact, the combined results of the prior single-injection trials indicate that the AP-013 KL 4 patients could report a difference of Ampion over saline that is 50% less than observed in the prior trials, and the clinical benefit of Ampion in both pain and function would still be statistically significant (p-value < 0.05)."

This sounds good. I hope that the difference does not reduce but statistically things are looking good.

Waiting anxiously for results. It they are good the price will go to da moon !!!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist